glp 1 agonists names GLP-1 receptor and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Adverse Effects of GLP-1 Receptor

Sleep Breath 23, 535542

Key points: In clinical trials, tirzepatide (Mounjaro) produced roughly double the average weight loss of liraglutide (Saxenda), though these were separate trials with different durations Tirzepatide at the 15 mg dose produced approximately 21% average weight loss over 72 weeks Liraglutide 3.0 mg produced approximately 8% average weight loss over 56 weeks Real-world data from Second Nature shows even greater results (22.1%) when tirzepatide is combined with behavioural support Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract

Dose adjustment of ACEI in patients treated with GLP1RAs is probably not required

Additionally, advancements in drug delivery systems have significantly enhanced the targeting and pharmacokinetics of natural compounds for PD, offering improved efficacy and reduced side effects

These results suggest that NRF2 is a necessary component of melatonin signaling pathways in ILC2s, linking the canonical circadian hormone to cellular redox machinery